

P.05/08

** TX STATUS REPORT **

AS OF MAR 26 2002 11:59 PAGE.01

#10/a 10-3102 RP

DATE TIME 32 03/26 11:58 TO/FROM MODE 917038729306 EC--S MIN/SEC PGS 00'30" 002 JOB# STATUS 0K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Roth et al.

) Art Unit:

1625

Serial No.

: 09/678,682

) Examiner:

Morris, P.

Filed

; October 3, 2000

Docket No.

: SUBSTITUTED INDOLINES WHICH INHIBIT RECEPTOR TYROSINE

KINASES

For

: 5/1275

Confirmation No.: 6798

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (attn: TC 1600 at 703-872-9306) on March 26,

2002.

By:

Alan Stempel

Reg. No. 28,991

Assistant Commissioner for Patents Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office action mailed on February 27, 2002, please enter the following elections.



ELECTIONS

Applicants hereby elect to prosecute claims directed to the invention of Group I, that is, the invention of claims 1-7, drawn to compounds and compositions, classified in classes 540, 544, 546 and 548, various subclasses.

Applicants further elect the following single disclosed species: 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone. The elected species is disclosed on page 226 as compound No. (473) and has the following structure:

The elections are made without traverse.

Respectfully submitted,

Alan Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 798-4868